DBV Technologies Shares Climb After VITESSE Phase 3 Data Shows Strong Peanut Patch Responses
DBV Technologies saw its stock rise after the company released expanded findings from the Phase 3 VITESSE trial for the VIASKIN Peanut Patch at the American Academy of Allergy, Asthma, and Immunology 2026 Annual Meeting. The data indicate substantially greater increases in eliciting dose among children treated with the patch versus placebo, while s…